Aim: To evaluate the cost-effectiveness of IDegLira versus basal-bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.
| INTRODUCTION
Diabetes is a well-characterised metabolic disorder known to affect approximately 6.2% of the UK population, with 2.9 million people estimated to have diabetes nationwide in 2015.
1 Type 2 diabetes mellitus accounts for approximately 90% of diabetes cases, and is primarily caused by insulin resistance, with progressive beta-cell loss eventually leading to insulin deficiency. 2, 3 Poor glycaemic control has been linked to an increased risk of diabetes-related complications, including retinopathy, nephropathy, autonomic nervous system malfunction, diabetic foot (possibly requiring amputation) and increased risk of stroke and myocardial infarction. [4] [5] [6] [7] [8] [9] [10] [11] The National Institute for Health and Care Excellence (NICE) outlined the most recent UK treatment guidelines for people with type 2 diabetes in 2015. 12 Evidence-based, patient-specific education and lifestyle modification should form the initial basis of treatment. If this proves unsuccessful in controlling blood glucose levels (inadequate control defined as a glycated haemoglobin [HbA1c] level of ≥7.5%
[53 mmol/mol]) then metformin should be administered as a first-line pharmacologic therapy, followed by intensification of therapy as the disease progresses according to patient preferences and multifactorial treatment targets. The combination of metformin with long-acting basal insulin should be considered an essential therapy for patients with advanced disease not achieving agreed HbA1c targets on current antidiabetic medications. 13 However, it has been reported that approximately 64% of patients with type 2 diabetes on basal insulin therapy experience inadequate glycaemic control, with 60% not receiving intensified treatment in a timely manner. 14, 15 At this stage, intensification to basal-bolus insulin therapy is typically recommended. While efficacious in terms of reducing HbA1c, such a treatment regimen is associated with weight gain and high risk of hypoglycaemic episodes. Additionally, the multiple daily injections required represent a more complex treatment regimen. These factors have been linked to reduced patient adherence, leading to impaired glycaemic control.
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A combination of basal insulin plus glucagon-like peptide-1 (GLP-1)
receptor agonists represents an alternative to basal-bolus insulin for patients with type 2 diabetes not achieving targets on basal insulin alone.
Such a combination takes advantage of the complementary mechanisms of action of the 2 interventions, as GLP-1 receptor agonists mitigate many of the undesirable side effects associated with basal insulin therapy, particularly weight gain and hypoglycaemia. 22 Insulin degludec/liraglutide (IDegLira) combines insulin degludec, a basal insulin therapy with a half-life of more than 24 h, and liraglutide, a GLP-1 receptor agonist, in a fixed-ratio, once-daily injection. 23 The recent 26-week, non-inferiority, treat-to-target DUAL VII trial compared the efficacy and safety of IDegLira versus a typical basal-bolus therapy (BBT) in patients with inadequate glycaemic control (HbA1c 7.0%-10.0%) on basal insulin therapy (20-50 IU insulin glargine U100 plus metformin). 24 
| Clinical events and disutilities
Rates of severe and non-severe hypoglycaemic episodes and changes in BMI associated with IDegLira and BBT were taken from the DUAL VII trial. 24 After adjustment for variations in baseline characteristics between the trial arms, IDegLira was associated with reduced fre- (Table 1) . 26 
| Medication resource use and costs
Mean daily doses of 40.1 dose steps for IDegLira, 52.7 IU for insulin glargine U100 and 32.3 IU for insulin aspart were used, based on the DUAL VII trial. 24 Injection frequency was once daily with IDegLira and 4-times daily with insulin glargine U100 plus insulin aspart (1 dose of insulin glargine U100 plus 3 bolus doses of insulin aspart), as this was the most common dosing schedule in DUAL VII. Each injection was assumed to be performed by a single, new needle, as recommended by the Forum for Injection Technique (FIT). 27 Patients receiving IDegLira were assumed to use 1 SMBG test per day, compared with 4 per day with BBT, as recommended in guidelines issued by Training, Research and Education for Nurses in Diabetes-United Kingdom (TREND-UK). 28 All costs were accounted from a healthcare payer perspective in pounds sterling (GBP). Annual costs of medications (IDegLira, insulin glargine U100 and insulin aspart), needles, and SMBG testing were based on wholesale acquisition costs ( Table 2) . 29 Direct costs associ- costs from MIMS UK. 29, 31, 32 No costs were applied to changes in BMI.
| Sensitivity analyses
A series of 1-way sensitivity analyses were performed to identify key drivers of model outcomes. The upper and lower 95% CIs for the approximately 15% less costly than first-to-market insulin glargine U100 [Lantus]) was applied in the basal-bolus regimen with no changes in clinical inputs. It was assumed that this biosimilar had the same efficacy and safety as first-to-market insulin glargine U100, but it should be noted that these treatments may not be identical, and approval of the use of biosimilars by the European Medicines Agency (EMA) does not involve any assessment or recommendation regarding interchangeability. 37 Further scenarios with biosimilar insulin glargine were evaluated, with a twice-daily injection regimen
(1 basal and 1 bolus injection) with BBT, and needle and SMBG costs excluded. 25, 26 Non-severe hypoglycaemia was defined as an episode that is blood-glucose confirmed by a plasma glucose value <3.1 mmol/L (56 mg/dL) with or without symptoms consistent with hypoglycaemia but which does not meet the ADA classification of a severe event. 
ICERs remained below the UK willingness-to-pay threshold of GBP 20 000 per QALY gained in all sensitivity analyses (Table 4) . 38, 39 Application of the upper and lower 95% CIs for BMI and hypoglycae- 
| DISCUSSION
The present analysis found that IDegLira was associated with an ICER of GBP 5924 per QALY gained versus BBT with insulin glargine U100 plus insulin aspart. This falls below the willingness-to-pay threshold of GBP 20 000 per QALY gained in the UK. 38, 39 Therefore, IDegLira was considered to be cost-effective versus BBT with insulin glargine U100 plus insulin aspart for the management of patients with type 2 diabetes in patients experiencing inadequate glycaemic control on a basal insulin regimen in the UK. Quality of life was improved by a significant decrease in non-severe hypoglycaemic episodes and a reduction, rather than an increase, in BMI. Cost increases were driven predominantly by the higher acquisition cost of IDegLira, but this was partially offset by cost savings associated with reduced use of needles, less SMBG testing, and fewer hypoglycaemic episodes (Figure 1 ). Avoidance of non-severe hypoglycaemic episodes was the largest contributor to reduced clinical event costs as, while they are less costly than severe episodes, they occur much more frequently (Figure 1 ). IDegLira Abbreviations: BMI, body mass index; QALYs, quality-adjusted life years. Non-severe hypoglycaemia was defined as an episode that is blood-glucose confirmed by a plasma glucose value <3.1 mmol/L (56 mg/ dL) with or without symptoms consistent with hypoglycaemia but which does not meet the ADA classification of a severe event.
study). 16, 18, 19 Further studies are needed to evaluate any long-term, real-world difference in patient adherence between IDegLira and BBT and any subsequent clinical impact that these differences may have.
The rationale for the comparison with BBT was based on the common treatment paradigm of diabetes, whereby patients typically intensify treatment to BBT following failure on basal insulin (with or without additional oral antidiabetic medications), and on the recent DUAL VII clinical trial, which directly compared IDegLira with BBT in this patient population. 13, 24 There is no current uniform national or international consensus for the optimal treatment regimen in type 2 diabetes, including the intensification steps beyond monotherapy, the ideal combination when basal insulin is introduced, and the In contrast with long-term models of type 2 diabetes, rates of complications were not included, as they were not expected to vary over the short-term time horizon of the analysis. [44] [45] [46] Furthermore, glycaemic control, a key driver of rates of diabetes-related complications, was equivalent in both arms. However, rates of diabetes-related complications can also be influenced by blood pressure, BMI and serum lipid levels, and IDegLira was associated with improvements in all of these risk factors versus BBT in the DUAL VII trial. 24 Therefore, it would be expected that complication rates would decrease with long-term IDegLira treatment. 4, 47, 48 The present model is intended to allow for a relatively quick but informative analysis that can complement, rather than replace, conventional long-term diabetes modelling, which typically projects outcomes (including microvascular and macrovascular complications and their associated impacts on costs and quality of life) over patient lifetimes. 49 A limitation of the analysis is the reliance on non-UK-specific patient data, as the participants of the DUAL VII study were recruited outside of the UK. However, it is common practice to adapt clinical trial data from multinational cohorts to country-specific analyses, with this methodology found throughout the published literature. 45, 46, [50] [51] [52] Moreover, the effect of IDegLira and BBT would not be expected to vary across the different country settings included in the DUAL VII trial and the UK.
A further limitation is the application of treatment effects for 52 weeks, as the DUAL VII trial concluded after 26 weeks. However, treatment effects displayed stability over the course of the DUAL VII trial, with benefits seen at the start maintained for the full trial duration. Additional studies of diabetes medications have also shown that treatment effects observed at 26 weeks are maintained at 52 weeks. 53 Therefore, it can be reasonably assumed that the benefits observed with IDegLira and BBT would be maintained over a 52-week treatment course.
Across a wide range of sensitivity analyses, ICERs remained under the willingness-to-pay threshold of GBP 20 000 per QALY in the UK. 38, 39 Sensitivity analyses identified the importance of needle and SMBG costs in driving outcomes, as removing these costs from the analysis increased the ICER to GBP 15 505 per QALY gained for IDegLira versus BBT (the second largest increase seen across the sensitivity analyses). Removal of these costs also contributed to the largest increase in the ICER, seen when these costs were excluded and the cost of biosimilar insulin glargine was applied in the BBT arm. Additionally, including a disutility for the increased 4-times daily injection frequency associated with BBT (comprising 1 basal and 3 bolus doses) resulted in the biggest decrease in the ICER, falling to GBP 2503 per QALY gained. These data indicate that injection frequency is associated with a potentially important quality-of-life burden, concurring with previous studies displaying patient preference for less complex treatment regimens. 16 The exclusion of a disutility for injection frequency from the base case analysis reinforces the conservative nature of the analysis, with IDegLira considered cost-effective despite this.
Application of upper and lower 95% CI for ETDs in BMI and hypoglycaemia for IDegLira and BBT resulted in only a minor change in ICERs (all within GBP 750 of the base case estimate), indicating the analysis is robust to plausible changes in the clinical inputs.
In conclusion, IDegLira is a cost-effective alternative to BBT with insulin glargine U100 plus insulin aspart for patients with type 2 diabetes inadequately controlled on basal insulin in the UK. As the recent DUAL VII trial has shown, IDegLira offers equivalent reductions in HbA1c to
BBT but provides a less complex treatment regimen and is associated with reduced risk of hypoglycaemic episodes and weight loss rather than weight gain. Further studies are needed to assess the long-term costeffectiveness of IDegLira in the UK, but the present analysis suggests that IDegLira is cost-effective versus BBT over a 1-year time horizon.
